- Home
- LONA vs NRXS Comparison
LONA vs NRXS Comparison
Compare LONA & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LONA | NRXS |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | 19 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.5M | 78.9M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | LONA | NRXS |
|---|---|---|
| Price | $7.50 | $7.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $10.00 | ★ $13.00 |
| AVG Volume (30 Days) | 29.4K | ★ 72.5K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,569,282.00 |
| Revenue This Year | N/A | $172.91 |
| Revenue Next Year | N/A | $115.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $4.21 | $2.20 |
| 52 Week High | $14.21 | $9.33 |
Technical Indicators
Market Signals| Indicator | LONA | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 47.14 | 54.85 |
| Support Level | $6.86 | $7.01 |
| Resistance Level | $9.78 | $7.54 |
| Average True Range (ATR) | 0.47 | 0.39 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 76.56 | 85.91 |
Price Performance
Historical ComparisonAbout LONA LeonaBio Inc. Common Stock
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).